Controlling the kinetics of interferon transgene expression for improved gene therapy

Journal of Drug Targeting

Volumn 20, Issue 9, 2012, Pages 764-769

  Watcharanurak, Kanitta ^a   Nishikawa, Makiya ^a   Takahashi, Yuki ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

CpG motifs; Enhancer; Non viral vector; Plasmid backbone; Plasmid DNA; Promoter

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERFERON; MINICIRCLE DNA; PLASMID DNA; PLASMID VECTOR;

ALLERGIC DISEASE; ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CPG ISLAND; CYTOPLASM; DNA MODIFICATION; DRUG SAFETY; ELECTROPORATION; ENHANCER REGION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; STATIC ELECTRICITY; TRANSGENE; VIRUS INFECTION;

ANIMALS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERFERONS; PLASMIDS; TRANSGENES;

EID: 84867615333     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.716848     Document Type: Article

References (42)

1. Ando M, Takahashi Y, Nishikawa M, Watanabe Y, Takakura Y. (2012). Constant and steady transgene expression of interferon-? by optimization of plasmid construct for safe and effective interferon-? gene therapy. J Gene Med, 14, 288-295.
2. Argyros O, Wong SP, Fedonidis C, Tolmachov O, Waddington SN, Howe SJ, Niceta M, Coutelle C, Harbottle RP. (2011). Development of S/ MAR minicircles for enhanced and persistent transgene expression in the mouse liver. J Mol Med, 89, 515-529.
3. Bracarda S, Eggermont AM, Samuelsson J. (2010). Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer, 46, 284-297.
4. Chen ZY, He CY, Ehrhardt A, Kay MA. (2003). Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther, 8, 495-500. (Pubitemid 37161471)
5. Chen ZY, He CY, Meuse L, Kay MA. (2004). Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther, 11, 856-864. (Pubitemid 38714589)
6. Chen ZY, Riu E, He CY, Xu H, Kay MA. (2008). Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther, 16, 548-556. (Pubitemid 351314995)
7. Edelstein M. (2012). Gene therapy clinical trials worldwide [Online]. John Wiley and Sons Ltd. Available: Http://www.wiley.com/ legacy/wileychi/ genmed/clinical/ [Accessed 24 April 2012].
8. Edelstein ML, Abedi MR, Wixon J. (2007). Gene therapy clinical trials worldwide to 2007-an update. J Gene Med, 9, 833-842. (Pubitemid 47543250)
9. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. (2004). Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med, 6, 597-602. (Pubitemid 40228075)
10. Harkins RN, Szymanski P, Petry H, Brooks A, Qian HS, Schaefer C, Kretschmer PJ, Orme A, Wang P, Rubanyi GM, Hermiston TW. (2008). Regulated expression of the interferon-beta gene in mice. Gene Ther, 15, 1-11. (Pubitemid 350284204)
11. Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K, Toyota H, Takahashi Y, Takahashi R, Watanabe Y, Takakura Y. (2010). Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol, 184, 2729-2735.
12. Huang M, Chen Z, Hu S, Jia F, Li Z, Hoyt G, Robbins RC, Kay MA, Wu JC. (2009). Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation, 120, S230-S237.
13. Kalanjeri S, Sterman D. (2012). Gene therapy in interventional pulmonology: Interferon gene delivery with focus on thoracic malignancies. Curr Resp Care Rep, 1, 54-66.
14. Kamimura K, Suda T, Zhang G, Liu D. (2011). Advances in Gene Delivery Systems. Pharmaceut Med, 25, 293-306.
15. Kawano H, Nishikawa M, Mitsui M, Takahashi Y, Kako K, Yamaoka K, Watanabe Y, Takakura Y. (2007). Improved anti-cancer effect of interferon gene transfer by sustained expression using CpGreduced plasmid DNA. Int J Cancer, 121, 401-406. (Pubitemid 46924040)
16. Kreiss P, Cameron B, Rangara R, Mailhe P, Aguerre-Charriol O, Airiau M, Scherman D, Crouzet J, Pitard B. (1999). Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res, 27, 3792-3798. (Pubitemid 29454426)
17. Lu J, Zhang F, Xu S, Fire AZ, Kay MA. (2012). The extragenic spacer length between the 5' and 3' ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors. Mol Ther. DOI: 10.1038/mt.2012.65.
18. Magnusson T, Haase R, Schleef M, Wagner E, Ogris M. (2011). Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations. J Gene Med, 13, 82-391.
19. Matsumoto K, Kubo H, Murata H, Uhara H, Takata M, Shibata S, Yasue S, Sakakibara A, Tomita Y, Kageshita T, Kawakami Y, Mizuno M, Yoshida J, Saida T. (2008). A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. Jpn J Clin Oncol, 38, 849-856.
20. Mayrhofer P, Schleef M, Jechlinger W. (2009). Use of minicircle plasmids for gene therapy. Methods Mol Biol, 542, 87-104.
21. Mehier-Humbert S, Guy RH. (2005). Physical methods for gene transfer: Improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev, 57, 733-753. (Pubitemid 40332600)
22. Mitsui M, Nishikawa M, Zang L, Ando M, Hattori K, Takahashi Y, Watanabe Y, Takakura Y. (2009). Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J Gene Med, 11, 435-443.
23. Nishikawa M, Hashida M. (2002). Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull, 25, 275-283. (Pubitemid 39663276)
24. Nishikawa M, Huang L. (2001). Nonviral vectors in the new millennium: Delivery barriers in gene transfer. Hum Gene Ther, 12, 861-870. (Pubitemid 32681851)
25. Nishikawa M, Nakayama A, Takahashi Y, Fukuhara Y, Takakura Y. (2008). Reactivation of silenced transgene expression in mouse liver by rapid, large-volume injection of isotonic solution. Hum Gene Ther, 19, 1009-1020.
26. Nordstrom JL. (2003). The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Steroids, 68, 1085-1094. (Pubitemid 37532434)
27. Platanias LC. (2005). Mechanisms of type-I- and type-II- interferonmediated signalling. Nat Rev Immunol, 5, 375-386.
28. Raab-Traub N. (2002). Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol, 12, 431-441. (Pubitemid 35370756)
29. Riu E, Grimm D, Huang Z, Kay MA. (2005). Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum Gene Ther, 16, 558-570. (Pubitemid 40740924)
30. Sadler AJ, Williams BR. (2008). Interferon-inducible antiviral effectors. Nat Rev Immunol, 8, 559-568. (Pubitemid 351913674)
31. Scheule RK. (2000). The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev, 44, 119-134.
32. Szymanski P, Kretschmer PJ, Bauzon M, Jin F, Qian HS, Rubanyi GM, Harkins RN, Hermiston TW. (2007). Development and validation of a robust and versatile one-plasmid regulated gene expression system. Mol Ther, 15, 1340-1347. (Pubitemid 46969873)
33. Takahashi Y, Nishikawa M, Takakura Y. (2012). Development of safe and effective nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector. Front Biosci (Schol Ed), 4, 133-141.
34. van Gaal EV, Hennink WE, Crommelin DJ, Mastrobattista E. (2006). Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy. Pharm Res, 23, 1053-1074. (Pubitemid 43946132)
35. Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J. (2008). A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: Novel findings from gene expression profiling and autopsy. J Gene Med, 10, 329-339. (Pubitemid 351517089)
36. Wu J, Xiao X, Zhao P, Xue G, Zhu Y, Zhu X, Zheng L, Zeng Y, Huang W. (2006). Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res, 12, 4702-4713. (Pubitemid 44297824)
37. Yates JL, Camiolo SM, Bashaw JM. (2000). The minimal replicator of Epstein-Barr virus oriP. J Virol, 74, 4512-4522. (Pubitemid 30237876)
38. Yew NS. (2005). Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev, 57, 769-780. (Pubitemid 40332602)
39. Yew NS, Cheng SH. (2004). Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy. Expert Opin Drug Deliv, 1, 115-125. (Pubitemid 40297960)
40. Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, Cheng SH. (2002). CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther, 5, 731-738. (Pubitemid 34619066)
41. Yin W, Xiang P, Li Q. (2005). Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal Biochem, 346, 289-294. (Pubitemid 41550259)
42. Zuo Y, Wu J, Xu Z, Yang S, Yan H, Tan L, Meng X, Ying X, Liu R, Kang T, Huang W. (2011). Minicircle-oriP-IFN?: A novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma. PLoS ONE, 6, e19407.